ARTICLES BY JOSEPH G. OBERLANDER
-
![Date marked on medicine container-GettyImages-2290387679]( "The Silent Threat To Clinical Trials: Why Shelf-Life Management Can Determine Study Success")
9/3/2026Shelf life is more than an expiration date. Explore how global trials can turn aging inventory into supply disruptions, added costs, and risks to patient treatment.
-
![Quality control and hygiene standards-GettyImages-2272407100]( "Optimizing CMO/CRO Partnerships To Improve Clinical Trial Supply Performance")
6/8/2026Strong CMO/CRO partnerships can reduce supply risk, improve forecasting, prevent packaging delays, and keep clinical trial product flowing reliably.
-
![pharmaceutical production plant, automation technology, bottles, vials-GettyImages-2213180417]( "Designing CNS Trial Supply Chains: A Technical Framework")
4/21/2026CNS trials demand precision supply chains. From DTP logistics to dynamic forecasting, small disruptions can compromise data, adherence, and outcomes.
-
![Supply chain disruptions-GettyImages-2270033976]( "Protecting Clinical Trials From Global Supply Disruptions")
4/17/2026Clinical trials are fragile. Supply chain disruptions like cold chain failures or single-source dependencies threaten patient safety and trial success.
-
![tablet for medicine management, stock research or inventory, Digital technology-GettyImages-1666055403]( "Bridging Preclinical Science And Trial Supply Success")
3/27/2026Bridging preclinical science and clinical supply ensures therapies reach patients efficiently. Early planning, collaboration, and flexible supply chains prevent costly delays.
Joseph G. Oberlander, Ph.D., PMP
Joseph G. Oberlander, Ph.D., PMP, is an experienced pharmaceutical development consultant and program manager. His consulting experience ranges from preclinical to Phase 3 programs, across multiple therapeutic areas (oncologic, metabolic, CNS) and drug modalities (NCE, biologics, biosimilars, generics, CGT), at clients ranging from virtual startups to large biopharma, and throughout the drug life cycle (from raw materials sourcing to finished goods use) for drug programs with global operations. His consulting focus includes deep expertise in clinical supply chain strategy and distribution logistics and in analytical and stability program management. In addition, he has significant research experience in neurobiology and is a published author contributing to the understanding of inherent biological sex differences in synaptic physiology and how these differences impact drug effects and deepen our understanding of preclinical disease models.